Our present study had two goals: (1) develop a true LMP1-expressing B cell lymphoma mouse model of disease, using stable transformation of the well-characterized mouse B cell line 38C13, and (2) compare the antitumor effects after vaccination with an LMP conjugated peptide epitope vaccine against the viral LMP1 antigen, or a full-length LMP1 plasmid DNA vaccine, in order to establish the mechanism of protection. The gene discussed is PDLIM7; the disease is B-cell non-Hodgkin lymphoma.